STOCK TITAN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

Rhea-AI Summary
AstraZeneca announces winners of the 2023 R&D Postdoctoral Challenge and will fund their postdoctoral positions at strategic R&D centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
Rhea-AI Summary
AstraZeneca will present new data at the ESMO Congress, showcasing the significance of datopotamab deruxtecan in lung and breast cancers. FLAURA2 data reinforces the effectiveness of TAGRISSO in EGFR-mutated lung cancer. IMFINZI plus LYNPARZA shows benefit in endometrial cancer. IMFINZI data in gastric cancer highlights potential of immunotherapy combinations. Nearly 100 abstracts will feature 19 approved and potential new medicines from AstraZeneca, including two late-breaking Presidential Symposia and 26 oral presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
AstraZeneca Foundation awards $2,170,318 in grants to 12 nonprofit organizations for healthcare disparities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
Rhea-AI Summary
Positive topline results from the TROPION-Breast01 phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival (PFS) compared to investigator’s choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR) positive, HER2 low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated with endocrine-based therapy and at least one systemic therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
ENHERTU recommended for approval in the EU for advanced non-small cell lung cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary
AstraZeneca partners with Future Biogas for 15-year agreement to supply biomethane gas, investing £100m in energy efficiencies. The partnership will reduce emissions by 20,000 tonnes CO2e and add renewable energy capacity to the national gas grid. AstraZeneca is on track to reduce GHG emissions by 98% by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
Rhea-AI Summary
AstraZeneca's FASENRA meets primary endpoint in Phase III trial for EGPA, demonstrating non-inferior rates of remission compared to mepolizumab
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
-
Rhea-AI Summary
AstraZeneca's TAGRISSO in combination with chemotherapy reduces the risk of disease progression by 38% compared to TAGRISSO alone for patients with EGFRm NSCLC. Median PFS extended by 8.8 months with the combination.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
-
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU shows positive results in Phase II trial for HER2-mutant lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
Rhea-AI Summary
ENHERTU shows strong and durable tumor responses in patients with HER2 mutant non-small cell lung cancer. Objective response rates of 49% and 56% were observed with 5.4 mg/kg and 6.4 mg/kg doses, respectively. Median progression-free survival was 9.9 months at 5.4 mg/kg and 15.4 months at 6.4 mg/kg. Favorable safety profile supports the use of ENHERTU. No new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

AZN Stock Data

212.97B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.